AMPH vs ANIP: fair value comparison
Amphastar Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ANIP currently sits closer to the top of our discount ranking. AMPH carries the stronger momentum grade.
| AMPH | ANIP | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $20.22 | $80.06 |
| 12-month range | $18.42–$30.81 | $75.22–$94.10 |
| Sector rank | #15 of 113 Healthcare | #11 of 113 Healthcare |
| Quality grade | C- | C- |
| Momentum grade | A | B |
| Leverage | Moderate | Moderate |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: AMPH fair value analysis · ANIP fair value analysis